A clinical trial has been undertaken in hospitalised COVID‐19 patients where the triple combination of IFN‐β, lopinavir–ritonavir, and ribavirin was compared with lopinavir–ritonavir and ribavirin (Hung et al., 2020; Shalhoub, 2020). This evidence concerns the gene IFNB1 and COVID-19.